As a result of losing weight, you can improve your sleep quality and reduce your risk of sleep apnea
This approval was based on clinical trials that showed significant loss in body weight when compared to a placebo after a year of treatment for non-diabetic individuals and those with type 2 diabetes
To mitigate the risks, the FDA recommends talking to your healthcare provider and filling prescriptions at state-licensed pharmacies
Gastrointestinal Effects Both medications can affect the digestive system, though through different mechanisms: Meloxicam can cause gastrointestinal adverse effects including dyspepsia, abdominal pain, nausea, andin more serious casesgastric ulceration or bleeding, particularly with prolonged use or in high-risk patients Wegovy commonly causes gastrointestinal side effects, especially during dose escalation, including nausea (occurring in up to 44% of patients), vomiting, diarrhoea, constipation, and abdominal discomfort When used together, there is a theoretical possibility that gastrointestinal side effects might be more pronounced , though this is not a formal interaction and varies considerably between individuals
Using longitudinal prescription databases, we examined dosage formulation distributions at 3-month intervals from baseline up to 12 months post-index for incident and prevalent users of the three GLP-1 RAs of interest in France and Italy